Glipizide is a sulfonylurea hypoglycemic agent, it acts mainly by increasing endogenous insulin secretion from beta cells of Langerhans Islet Tissue in pancreas and increases the sensitivity of insulin in tissue.And decreases the production of glucose in type II of non-insulin dependent diabetic mellitus patients.

– It should be used with caution in patients with renal and hepatic impairment.– It is necessary during excessive exercise as hypoglycemia may be provoked and patient should be instructed to take their meals regularly.

The usual initial dose is 2.5 mg to 5 mg daily, usually is taken 15–30 minutes before breakfast.Dosage may be adjusted as doctor advice to the maximum 20 mg daily. The sustained release of this product adjust glucose blood level, with the maximum concentration of drug in blood after 6–12 hours from taking.